Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H11F3N2O3 |
Molecular Weight | 276.2118 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
InChI
InChIKey=MKXKFYHWDHIYRV-UHFFFAOYSA-N
InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
Molecular Formula | C11H11F3N2O3 |
Molecular Weight | 276.2118 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00499Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/flutamide.html
Sources: http://www.drugbank.ca/drugs/DB00499
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/flutamide.html
Flutamide is a nonsteroidal antiandrogen. In animal studies, flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen, e.g. castration. Elevations of plasma testosterone and estradiol levels have been noted following flutamide administration. Flutamide blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen. Flutamide is used for the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6055125
Curator's Comment: flutamide crosses the blood brain barrier and is capable of exerting influence on central structures through interactions with androgen receptors.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612518 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21600678 |
0.9 µM [IC50] | ||
Target ID: CHEMBL1871 Sources: http://www.drugbank.ca/drugs/DB00499 |
102.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | EULEXIN Approved UseFlutamide capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate. Launch Date1989 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
53.4 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10073738 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
112.7 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2754024 |
250 mg 3 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
25.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2754024 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
96.4 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10073738 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
212.1 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2754024 |
250 mg 3 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
63 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2754024 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10073738 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Disc. AE: Abdominal pain, Vomiting... Other AEs: Flatulence, Diarrhea... AEs leading to discontinuation/dose reduction: Abdominal pain (12 patients) Other AEs:Vomiting (8 patients) Headache (9 patients) Hypertransaminasemia (3 patients) Fatty liver (1 patient) Weight gain (5 patients) Flatulence (15 patients) Sources: Diarrhea (5 patients) Dry skin (10 patients) Nephrolithiasis (1 patient) Leg pain (2 patients) Dyslipidemia (4 patients) Fluid retention (4 patients) Epigastralgia (3 patients) Dyspepsia (2 patients) Nausea (9 patients) Vaginal infection (1 patient) Constipation (3 patients) |
250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Disc. AE: Diarrhea, Impaired liver function... Other AEs: Hot flushes, Breast tenderness... AEs leading to discontinuation/dose reduction: Diarrhea (severe, 1.3%) Other AEs:Impaired liver function (4%) Gynecomastia (1.3%) Hot flushes (all grades, 25%) Sources: Breast tenderness (all grades, 49%) Nausea and vomiting (all grades, 22%) Appetite lost (all grades, 17%) Diarrhea (all grades, 16%) Hot flushes (severe, 4%) Breast tenderness (severe, 7%) Nausea and vomiting (severe, 1.3%) Appetite lost (severe, 1.3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nephrolithiasis | 1 patient | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Vaginal infection | 1 patient | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Fatty liver | 1 patient Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Dry skin | 10 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Abdominal pain | 12 patients Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Flatulence | 15 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Dyspepsia | 2 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Leg pain | 2 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Constipation | 3 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Epigastralgia | 3 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Hypertransaminasemia | 3 patients Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Dyslipidemia | 4 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Fluid retention | 4 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Diarrhea | 5 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Weight gain | 5 patients Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Vomiting | 8 patients Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Nausea | 9 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Headache | 9 patients Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Gynecomastia | 1.3% Disc. AE |
250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Impaired liver function | 4% Disc. AE |
250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Diarrhea | all grades, 16% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Appetite lost | all grades, 17% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Nausea and vomiting | all grades, 22% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Hot flushes | all grades, 25% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Breast tenderness | all grades, 49% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Appetite lost | severe, 1.3% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Nausea and vomiting | severe, 1.3% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Diarrhea | severe, 1.3% Disc. AE |
250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Hot flushes | severe, 4% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Breast tenderness | severe, 7% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
unlikely | ||||
unlikely | ||||
yes [Ki 1 uM] | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/18599551/ |
||||
PubMed
Title | Date | PubMed |
---|---|---|
Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats. | 2001 |
|
A risk-benefit assessment of pharmacological therapies for hirsutism. | 2001 |
|
Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. | 2001 |
|
[What is the role of hormonal treatments in acne?]. | 2001 Apr |
|
[Clinical efficacy of treatment with low-dose flutamide in maximum androgen blockade therapy]. | 2001 Apr |
|
[Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials]. | 2001 Apr |
|
Feasibility and potential gains of enhancing the subacute rat study protocol (OECD test guideline no. 407) by additional parameters selected to determine endocrine modulation. A pre-validation study to determine endocrine-mediated effects of the antiandrogenic drug flutamide. | 2001 Apr |
|
[Hirsutism, flutamide and hepatotoxicity]. | 2001 Apr |
|
Appropriate column configurations for the rapid analysis and semipreparative purification of the radiolabeled drug flutamide by high-performance liquid chromatography. | 2001 Apr 20 |
|
Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. | 2001 Apr 27 |
|
Androgen-induced up-regulation of tubulin isoforms in neuroblastoma cells. | 2001 Aug |
|
Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. | 2001 Aug |
|
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. | 2001 Aug |
|
Testosterone suppresses spermatogenesis in juvenile spermatogonial depletion (jsd ) mice. | 2001 Aug |
|
Regulation of keratinocyte growth factor receptor and androgen receptor in epithelial cells of the human prostate. | 2001 Aug |
|
Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. | 2001 Aug |
|
Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. | 2001 Aug |
|
Androgen-mediated development in male rat offspring exposed to flutamide in utero: permanence and correlation of early postnatal changes in anogenital distance and nipple retention with malformations in androgen-dependent tissues. | 2001 Aug |
|
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. | 2001 Aug 1 |
|
Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. | 2001 Aug 5 |
|
[Anemia and neoadjuvant hormone therapy in radical surgery of localized cancer of the prostate]. | 2001 Feb |
|
M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL. | 2001 Jul |
|
The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein. | 2001 Jul 27 |
|
Virilization of the urogenital sinus of the tammar wallaby is not unique to 5alpha-androstane-3alpha,17beta-diol. | 2001 Jul 5 |
|
Kap promoter analysis in vivo: a regulatory role for a truncated L1 repeat. | 2001 Jul 5 |
|
Strain sensitivity differences in the Hershberger assay. | 2001 Jul-Aug |
|
Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. | 2001 Jun |
|
Sex differences in infant rhesus macaque separation-rejection vocalizations and effects of prenatal androgens. | 2001 Jun |
|
Developmental and hormonal regulation of type II DNA topoisomerase in rat testis. | 2001 Jun |
|
Steroid-sensitive gene-1 is an androgen-regulated gene expressed in prostatic smooth muscle cells in vivo. | 2001 Jun |
|
Modulation of gene expression by androgen and oestrogens in the testis and prostate of the adult rat following androgen withdrawal. | 2001 Jun 10 |
|
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. | 2001 Jun 15 |
|
The biological effect of phthalate esters on transabdominal migration of the testis in fetal rats in comparison with the antiandrogen flutamide. | 2001 Mar |
|
A novel isoform of human fibroblast growth factor 8 is induced by androgens and associated with progression of esophageal carcinoma. | 2001 May |
|
Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. | 2001 May |
|
Effects of acute stanozolol treatment on puberty in female rats. | 2001 May |
|
Testosterone receptor blockade restores cellular immunity in male mice after burn injury. | 2001 May |
|
Dissection and weighing of accessory sex glands after formalin fixation, and a 5-day assay using young mature rats are reliable and feasible in the Hershberger assay. | 2001 May 11 |
|
Initial induction and subsequent reduction of alpha(2u)-globulin in urine and serum of mature male rats after repeated intraperitoneal injections of (anti)estrogen. | 2001 May 11 |
|
Chemical andropause and amyloid-beta peptide. | 2001 May 2 |
|
Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. | 2001 May 24 |
|
Quantification of antiandrogen effect determined by Lightcycler technology. | 2001 May 28 |
|
Neonatal exposure to potent and environmental oestrogens and abnormalities of the male reproductive system in the rat: evidence for importance of the androgen-oestrogen balance and assessment of the relevance to man. | 2001 May-Jun |
|
Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. | 2001 Nov |
|
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. | 2001 Nov 1 |
|
Replacement of surgical castration by GnRH-inhibition or Leydig cell ablation in the male rat Hershberger antiandrogen assay. | 2001 Oct |
|
Attenuation of vascular endothelial dysfunction by testosterone receptor blockade after trauma and hemorrhagic shock. | 2001 Oct |
|
Flutamide-induced acute hepatitis in advanced prostate cancer patients. | 2001 Sep |
|
Differential gene expression in response to methoxychlor and estradiol through ERalpha, ERbeta, and AR in reproductive tissues of female mice. | 2001 Sep |
|
Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. | 2001 Sep 5 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/flutamide.html
For use in locally confined stage B2-C and stage D2 metastatic carcinoma of the prostate: 250 mg orally every 8 hours.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19307032
Flutamide inhibited spiggin production in vitro at a concentration as low as 10(-12) M in cultures of primed female stickleback kidney cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:43:06 GMT 2023
by
admin
on
Sat Dec 16 17:43:06 GMT 2023
|
Record UNII |
76W6J0943E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175560
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
||
|
WHO-ATC |
L02BB01
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
||
|
NDF-RT |
N0000000243
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
||
|
NCI_THESAURUS |
C242
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
||
|
NCI_THESAURUS |
C1915
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
||
|
WHO-VATC |
QL02BB01
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
||
|
LIVERTOX |
NBK548908
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
76W6J0943E
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
FLUTAMIDE
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
DB00499
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
1285851
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
5132
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
m5508
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL806
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
4508
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | RxNorm | ||
|
236-341-9
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
100000092094
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
13311-84-7
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
1223
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
3483
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
3397
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
D005485
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
6943
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
76W6J0943E
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
DTXSID7032004
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
C509
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
215876
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY | |||
|
SUB07756MIG
Created by
admin on Sat Dec 16 17:43:07 GMT 2023 , Edited by admin on Sat Dec 16 17:43:07 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (UV)
EP
|
||
|
BINDER->LIGAND |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TARGET -> INHIBITOR |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||